阿尼鲁单抗与贝利尤单抗对系统性红斑狼疮心血管疾病风险的比较
该研究利用TriNetX电子健康记录数据模拟目标试验,纳入无既往心血管疾病的成人SLE患者,比较启动阿尼鲁单抗或贝利尤单抗后的三年心血管结局。倾向评分匹配后分析显示,与贝利尤单抗相比,阿尼鲁单抗与心肌梗死、心力衰竭、缺血性卒中和MACE风险降低相关。结论提示阿尼鲁单抗可作为心血管风险较高SLE患者的安全治疗选择,但需前瞻性研究确认因果。
要点
- 阿尼鲁单抗组心肌梗死风险低于贝利尤单抗组(HR 0.63;95%CI 0.40-0.91)。
- 阿尼鲁单抗组心力衰竭风险低于贝利尤单抗组(HR 0.55;95%CI 0.39-0.75)。
- 阿尼鲁单抗组MACE风险低于贝利尤单抗组(HR 0.65;95%CI 0.37-0.89)。
核心结论
- 在无既往心血管疾病的成人SLE患者中,阿尼鲁单抗治疗与贝利尤单抗相比与更低的心血管疾病风险相关。
- 结果支持将阿尼鲁单抗视为安全治疗选择,尤其适用于心血管风险增高的SLE人群。
- 需前瞻性研究以确立因果关系。
研究设计与样本
- 采用模拟目标试验设计,使用TriNetX网络中67个医疗组织的电子健康记录数据(2020-2025年)。
- 纳入启动阿尼鲁单抗或贝利尤单抗且无既往心血管疾病的成人SLE患者。
- 通过倾向评分匹配平衡人口学、合并症、实验室数据和用药情况。
主要发现
- 匹配前阿尼鲁单抗组1091例、贝利尤单抗组7492例,平均年龄分别为45.6岁和43.7岁。
- 匹配后队列包含1084对,平均年龄分别为45.6岁和46.0岁。
- 与贝利尤单抗相比,阿尼鲁单抗与心肌梗死风险降低相关(HR 0.63;95%CI 0.40-0.91)。
- 与贝利尤单抗相比,阿尼鲁单抗与心力衰竭风险降低相关(HR 0.55;95%CI 0.39-0.75)。
- 与贝利尤单抗相比,阿尼鲁单抗与缺血性卒中(HR 0.50;95%CI 0.26-0.94)和MACE(HR 0.65;95%CI 0.37-0.89)风险降低相关。
临床怎么用
- 对于无既往心血管疾病的成人SLE患者,选择阿尼鲁单抗可能较贝利尤单抗更有利于降低三年心血管事件风险。
- 对心血管风险增高的SLE患者,可考虑将阿尼鲁单抗作为治疗选项之一。
局限性
- 研究为基于电子健康记录的模拟目标试验,无法确立因果关系。
- 需前瞻性研究进一步验证结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Current guidelines recommend anifrolumab and belimumab as comparably viable immunosuppressive therapies for active systemic lupus erythematosus (SLE), yet comparative evidence remains limited. Patients with SLE have increased cardiovascular disease (CVD) risk, with dysregulated type I interferon (IFN-I) signaling implicated in disease pathogenesis. We evaluated whether anifrolumab, an IFN-I receptor antagonist, or belimumab confers differing CVD risks to inform treatment selection and patient counseling. METHODS: We conducted an emulated target trial using electronic health record data from 67 health care organizations in the TriNetX network (2020-2025). Adults with SLE initiating anifrolumab or belimumab without prior CVD were included. Propensity score matching balanced demographics, comorbidities, laboratory data, and medication use. Outcomes included three-year risks of myocardial infarction (MI), heart failure (HF), ischemic stroke, and major adverse cardiovascular events (MACEs). Cox regression estimated hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: Before matching, 1,091 patients received anifrolumab and 7,492 received belimumab (mean ages 45.6 and 43.7 years, respectively). After matching, the cohort included 1,084 pairs with mean ages of 45.6 and 46.0 years, respectively. Compared with belimumab, anifrolumab treatment was associated with lower risks of MI (HR 0.63; 95% CI 0.40-0.91), HF (0.55; 0.39-0.75), ischemic stroke (0.50; 0.26-0.94), and MACE (0.65; 0.37-0.89). CONCLUSION: Anifrolumab treatment was associated with lower CVD risk compared with belimumab in patients with SLE, supporting its consideration as a safe therapeutic option, particularly for populations with increased CVD risk. Prospective studies are needed to firmly establish causality.
引用
- Mahajan A, Whittelsey M, Vleugels RA, et al. Anifrolumab Versus Belimumab for Cardiovascular Disease Risk in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2026. PMID: 42565362. doi:10.1002/art.70293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。